MHMaryatun Hasan

Maryatun Hasan

*This is an algorithmically generated author record based on publicly available information.

Maryatun Hasan has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Agung Pranata

    Universitas Syiah Kuala

    1 shared publication
  • Darmawi Darmawi

    Faculty of Veterinary Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia

    1 shared publication
  • Kurnia F. Jamil

    Department of Internal Medicine, Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia

    1 shared publication
  • Maimun Syukri

    Department of Internal Medicine, Dr. Zainoel Abidin Hospital, Banda Aceh, Indonesia

    1 shared publication
  • Muhammad Alif Naufal

    Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia

    1 shared publication
  • Wahyu Eka Sari

    Center for Tropical Veterinary Studies-One Health Collaboration Center, Universitas Syiah Kuala, Banda Aceh, Indonesia; Veterinary Public Health Laboratory, Faculty of Veterinary Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia

    1 shared publication

Latest Publications

  • Open Access

    The effect of statin use on vascular inflammatory biomarkers in people living with HIV: A living systematic review of randomized controlled trials

    by Maryatun Hasan, Kurnia F. Jamil, Darmawi Darmawi, Maimun Syukri, Muhammad Alif Naufal

    Objective: To evaluate the effect of statin therapy on biomarkers of vascular inflammation in people living with HIV (PLWH). Methods: We conducted a living systematic review of randomized controlled trials (RCTs). We searched Scopus, PubMed, Cochrane Library, and Scilit up to April 4, 2025, with a predefined plan for ongoing evidence surveillance and updating. Nine RCTs involving 1 721 participants were included. Data were extracted on changes in key biomarkers, including interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), soluble CD14 (sCD14), soluble CD163 (sCD163), oxidized LDL (oxLDL), and lipoprotein-associated phospholipase A 2 (Lp-PLA 2 ). The Cochrane Risk of Bias (RoB 2) tool was used for quality assessment. This review is not intended to be retired from the living mode at this stage. Results: Statin therapy significantly reduced key biomarkers of monocyte activation and vascular inflammation, particularly IL-6 and sCD14, with effects being most consistent and pronounced with pitavastatin. Pitavastatin also demonstrated greater efficacy in reducing oxLDL and Lp-PLA 2 compared to other statins. Reductions in hs-CRP were inconsistent across studies. A critical finding was that treatment duration was a major modifier of effect, with interventions lasting ≥12 months yielding substantially greater anti-inflammatory benefits. The mechanistic profile suggests statins specifically target the LPS-sCD14 pathway of innate immune activation, which is highly relevant to HIV pathogenesis. Conclusions: Pitavastatin emerges as the most effective statin for reducing vascular inflammation in PLWH, offering a targeted strategy to mitigate cardiovascular disease risk in this population. These findings, derived from the current iteration of a living systematic review, support the use of long-term pitavastatin therapy for PLWH with evidence of residual inflammation and highlight the need for its inclusion in future clinical guidelines as new evidence continues to emerge.

  • Open Access

    The prevalence of long COVID symptoms in Indonesia: a cross-sectional study in Aceh

    by Maryatun Hasan, Wahyu Eka Sari, Agung Pranata

    Introduction: It is estimated that the long-term consequences of Coronavirus Disease 2019 (COVID-19) can be significant problems since they cause prolonged clinical manifestations after COVID-19. The aim of this study was to investigate patients with long-term effects of COVID-19 in Aceh Province, Indonesia. Methods: A cross-sectional study was conducted on COVID-19 patients in Aceh, Indonesia using an online survey software tool. The COVID-19 survivors were contacted after a diagnosis of COVID-19 at least 14 days after a negative real time polymerase chain reaction (RT-PCR) result. Results: A total of 303 respondents were contacted after a diagnosis of COVID-19 at least 14 days after a negative RT-PCR result. The results showed that 31% experienced long COVID until the 14th to 15th day of the month, while 69% did not offer long COVID symptoms. The most common symptoms experienced by the patients were fatigue (9.9%), headache (8.7%), and joint and muscle pain (8.1%). Other symptoms reported by COVID-19 survivors were polypnea and shortness of breath, sleep disturbances, coughing, hair loss, palpitations, runny nose, stuffy nose, mental health problems such as anxiety, impaired concentration and depression. The long COVID symptoms were more experienced by female respondents (64.9%) than male respondents (35.1%). Conclusion: Our data suggested that the symptoms of long COVID or long-term consequences of COVID-19 were relatively high. Therefore, measures should be taken to prevent long-term effects among COVID-19 survivors.